Proteasome inhibition prevents development of experimental dermal fibrosis. (Q54564157)

1 June 2018

title

Proteasome inhibition prevents development of experimental dermal fibrosis. (English)

1 reference

1 June 2018

author

Mehmet Tuzcu

4

1 reference

1 June 2018

Ibrahim Hanifi Ozercan

5

object named as

Ibrahim Hanifi Ozercan

1 reference

1 June 2018

Kazim Sahin

6

object named as

Kazim Sahin

1 reference

1 June 2018

Suleyman Serdar Koca

1

object named as

Suleyman Serdar Koca

1 reference

1 June 2018

author name string

Metin Ozgen

2

1 reference

1 June 2018

Ferda Dagli

3

1 reference

1 June 2018

Ahmet Isik

7

1 reference

1 June 2018

publication date

1 June 2012

1 reference

1 June 2018

published in

Inflammation

1 reference

1 June 2018

volume

35

1 reference

1 June 2018

issue

3

1 reference

1 June 2018

page(s)

810-817

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s10753-011-9380-y

exact match

0 references

cites work

Systemic scleroderma. Clinical and pathophysiologic aspects

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Scleroderma--clinical and pathological advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

New developments in the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Interleukin-1, Interleukin-2, Interleukin-4, Interleukin-6, Tumor Necrosis Factor α, and Interferon-γ Levels in Sera from Patients With Scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

The proteasome: a worthwhile target for the treatment of solid tumours?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Proteasome inhibition induces hepatic stellate cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

New insights into the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Early T cell activation in the skin from patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

The role of NF-kappaB in the regulation of cell stress responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

IkappaB kinases: key regulators of the NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Systemic sclerosis: a prototypic multisystem fibrotic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Effectiveness of etanercept in bleomycin-induced experimental scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

On and off: proteasome and TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Reactive oxygen species mediate crosstalk between NF-kappaB and JNK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Requirement of transforming growth factor beta-activated kinase 1 for transforming growth factor beta-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

Proteasome inhibition modulates kinase activation in neural cells: relevance to ubiquitination, ribosomes, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10753-011-9380-Y

The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity

21 January 2018

1 reference

12 December 2020

Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB.

1 reference

12 December 2020

Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis

1 reference

12 December 2020

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

1 reference

12 December 2020

Systemic sclerosis: an update.

1 reference

12 December 2020

[Effects of TGFbeta1 on the transcriptional activity of SP1, AP1 and Smad3-Smad4 in lung fibroblasts]

1 reference

12 December 2020

The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach

1 reference

12 December 2020

Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts

1 reference

12 December 2020

Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts

1 reference

12 December 2020

Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma

1 reference

12 December 2020

10.1007/S10753-011-9380-Y

Identifiers

DOI

1 reference

1 June 2018

PubMed ID

21882074

1 reference

1 June 2018